ABSTRACT Diabetic (DB) mice exhibit significant resistance to hepatotoxicants. The role of peroxisome proliferator receptor (PPAR)-α activation in diabetes, in protection against lethal acetaminophen (APAP) challenge, was investigated. Upon treatment with APAP (600 mg/kg, i.p., a LD 100 dose in wild-type [WT] non-DB mice), WT-DB mice showed only 30% mortality and 40% less liver injury as measured by alanine aminotransferase and histopathology. In contrast, diabetes in PPAR knockout (PPAR-α −/− ) mice failed to protect against APAP toxicity, suggesting the importance of PPAR-α in diabetes-induced protection. S-phase DNA synthesis and PCNA immunohistochemical staining after injury showed early and robust tissue repair in WT-DB mice, but not in the PPAR-α −/− -DB mice. Microarray analyses were performed on livers from non-DB and DB (WT and PPAR-α −/− ) mice at 0 and 12 h after APAP. Microarray data were confirmed via real-time polymerase chain reaction analysis of several genes, including stress response, immediate early genes, DNA damage, heat shock proteins, and cell cycle regulators, followed by Western analyses of selected proteins. Gel shift assays revealed higher activation of nuclear factor-κB in WT-DB mice after APAP treatment. These findings suggest PPAR-α activation as a hepatoprotective adaptive response mediating protection against APAP in diabetes.
between one-third and two-thirds of the lobular structure affected; 4, severe, defined as greater than two-thirds of the lobular structure affected; 5, more severe, defined as damage to most of the parenchyma of the liver.
H-T incorporation into hepatonuclear DNA
DNA synthesis was measured by 3 H-T incorporation into hepatonuclear DNA as described previously (1, 2) . Briefly, after a single i.p. injection of 3 H-T (10 µCi) 2 h before the mice were killed, under diethyl ether anesthesia, hepatic nuclei were isolated by sucrose gradient centrifugation. DNA was estimated by diphenylamine reaction in the supernatant. Radiolabeled 3 H-T in the supernatant was estimated using a liquid scintillation counter (Packard, Meriden, CT).
PCNA immunohistochemistry
The PCNA immunohistochemical analysis was conducted using the procedure described by Greenwell et al. (18) , as extensively used in previous work (1, 2, 16, 17) . For quantitation of PCNA-positive cells, 2000 cells were counted per slide. At least three slides from three separate animals were examined per group per time point. The nuclei of G 0 cells were blue. G 1 cells had light brown nuclei, and S-phase nuclei were stained dark brown. G 2 cells showed brown cytoplasmic staining with or without brown speckling of the nucleus. M cells were identified by mitotic ( Fig. 1 and 2 ) (16, 17) .
Analysis of hepatic microsomal Cyp2e1, 1a2, and Cyp4a proteins
Hepatic microsomes from non-DB and DB, rats and mice, euthanised on day 10 (n=4) were prepared by differential ultracentrifugation using the method described previously (2, 19) . Microsomal protein concentration was determined by the Bradford method, using the Bio-Rad (Hercules, CA) Protein Assay. Hepatic P450 isozymes were estimated using SDS-PAGE followed by standard Western blot. For detecting Cyp2e1, 1a2, and Cyp4a proteins, membranes were incubated with primary (goat) antibodies against respective proteins procured from Gentest (Woburn, MA). The blots were then further incubated with anti-goat IgG (Sigma) conjugated to horseradish peroxidase and visualized using a chemiluminescence kit obtained from Pierce Biochemicals (Rockford, IL). Blots were scanned using a GS-700 imaging densitometer (BioRad) and quantitated using Quantity One software (Bio-Rad). Microsomal Cyp2e1 activity was estimated via p-nitrophenol hydroxylase assay (20) .
Assessment of gene expression in non-DB and DB, WT and PPAR-α
−/− mice Livers were excised from non-DB and DB mice (n=4) 12 h after administration of either APAP (600 mg/kg, i.p.) or saline, frozen in liquid nitrogen, and stored at -75°C until required. Total RNA was extracted from mice livers (n=4 per group per time point, pooling equal amounts of liver tissue), using Trizol reagent and purified using RNeasy columns (Qiagen, Valencia, CA). Two to 5 µg of total RNA was converted to [α-32 P]-dATP-labeled cDNA prob,e using Moloney murine leukemia virus reverse transcriptase and the Atlas customer array-specific cDNA synthesis primer mix, and purified with Nucleospin column (Clontech, Palo Alto, CA). Three separate hybridizations on three different membranes were carried out for each group at every time point. The membrane was prehybridized with ExpressHyb (Clontech) for 60 min at 68°C, followed by hybridization overnight at 68°C. The membranes were then washed four times in 2× SSC/1% SDS for 30 min each, and two times in 0.1× SSC/0.5% SDS for 30 min. The membranes were then sealed with plastic wrap and exposed to a Molecular Dynamics Phosphoimager screen. The images were analyzed densitometrically using Atlas Image 2.01 software (Clontech). The gene expression intensities were first corrected with the local background before normalizing globally. Cluster analysis between treatment groups was done using Cluster software. A companion software, TreeView, was used for the presentation of data.
Real-time quantitative polymerase chain reaction (RT-PCR) analyses
RT-PCR utilizes the "real-time" monitoring of DNA amplification within the PCR tube aided by fluorescent DNA binding dyes (21, 22) . In this case, fluorescence resulting from nonspecific binding of SYBR Green to double-stranded DNA was measured. The fluorescence during the PCR reaction follows characteristic phases: exponential, linear, and ultimately a plateau. The number of cycles needed for the amplification-associated fluorescence to reach a specific threshold level of detection (C T value) is inversely proportional to the initial amount of nucleic acid that was in the original sample. Relative quantitation of mRNA levels for specific genes (Table 3) identified from the analysis was determined using RT-PCR. Reactions were carried out according to the manufacturer's instructions for AmpliTag Gold and the ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA). Briefly, 100 ng of total RNA was transcribed to single-stranded cDNA. Reverse transcription products were then amplified by PCR, using oligonucleotides from Sigma Genosys (St. Louis, MO). Hepatic RNA from four separate animals in each group was analyzed in duplicate. Results are expressed as average antilog of threshold cycle (C T ) value relative to WT-non-DB mice at 0 h after APAP treatment.
Gel shift assay of nuclear factor (NF)-κB
Nuclear protein was isolated from liver tissues at 0, 4, and 12 h after APAP treatment as described by Parrish et al. (23) . Gel shift assay was performed using gel shift assay systems from Promega (Madison, WI) according to the manufacturer's directions. Subsequent to electrophoresis at room temperature, gels were dried and exposed to X-Omat film (Eastman Kodak, Rochester, NY) for autoradiography. Blots were scanned using a GS-700 imaging densitometer (Bio-Rad).
Assessment of cyclin D1, p38 MAPK, ERK1/2, and HSP70 proteins
Total liver homogenates were made at 0 and 12 h after APAP treatment by pooling equal amounts of liver from four separate animals per group per time point. Total protein (100 µg) was subjected to electrophoresis on 12% Tris-HCl gels and transferred onto 0.25 µm nitrocellulose membranes. After blocking with 5% nonfat milk for 1 h, membranes were incubated overnight with primary antibodies at 4°C (anti-cyclinD1, anti-erk1/2, and anti-phospho-p38 MAPK from Cell Signaling Technology, Beverly, MA; and anti-HSP70 from Santa Cruz Biotechnology, Santa Cruz, CA). Membranes were further incubated with anti-goat/anti-rabbit or anti-mouse secondary antibodies conjugated to horseradish peroxidase and visualized using a chemiluminescence kit obtained from Pierce Biochemicals. Blots were scanned using a GS-700 imaging densitometer (Bio-Rad).
Assessment of role of tissue repair by colchicine (CLC) antimitosis
CLC antimitotic intervention has been previously used to examine the role of cell division in ultimate outcome of hepatotoxic injury in several models (1, 2, (24) (25) (26) (27) (28) (29) (30) (31) (32) . CLC is known to exert its antimitotic effects by microtubule perturbations (32, 34) . In addition, CLC also inhibits Sphase DNA synthesis by inhibition of thymidine kinase and thymidylate synthetase (35) . At low doses (1 mg/kg), CLC is devoid of toxicity and does not cause any adverse effects on liver histology or on liver function (24) . On day 10 of diabetes, two groups of WT-DB mice were treated with APAP (600 mg/kg, i.p., basic saline). One group was given CLC (1 mg/kg, i.p. in saline) at 2 and 30 h after APAP treatment, and the other group received saline as control at the same time points. A third group of WT-DB mice was given CLC alone, without receiving any APAP. Mice were observed twice daily for 14 days, and survival/mortality was recorded.
Statistical analysis
All Western blots were scanned using a GS-700 imaging densitometer (Bio-Rad)) and quantitated using Quantity One software (Bio-Rad). Data are expressed as means ±SE. SPSS software package version 11.0 (SPSS Inc., Chicago, IL) was used to perform all statistical tests. Statistical significance between DB and non-DB groups at the same time point was analyzed by Student's t test. Equality of variances was tested using Levene's test for equality of variance. Statistical significance between DB and non-DB groups vs. respective controls (at 0 time point) was evaluated using one-way ANOVA, followed by Duncan's multiple range test. The criterion for significance was P≤ 0.05.
RESULTS

Induction of diabetes and comparative lethality in WT and PPAR-α
−/− mice As expected, WT-DB and PPAR-α −/− -DB mice showed significantly greater plasma glucose on day 10 compared with WT-non-DB and PPAR-α −/− -non-DB mice (Table 1) . Also as expected, all mice in the WT and PPAR-α −/− non-DB groups died by 24 h after APAP administration.
However, 70% of the WT-DB mice escaped death from the same dose of APAP (Table 1) . However, the protection conferred by diabetes was lost in the PPAR-α −/− -DB mice, which died between 36 and 48 h after APAP treatment (80% mortality). Interestingly, onset of toxicity in the PPAR-α −/− DB mice was delayed.
Assessment of liver injury
Plasma ALT throughout the time course after APAP administration was significantly higher in the WT and PPAR-α −/− non-DB mice compared with their diabetic counterparts (Fig. 1A) .
Because all non-DB mice died around 24 h, data after this time point in the respective groups are not available. The liver injury (ALT elevation) in the WT-DB mice was 50% lower than in WTnon-DB mice and regressed after 12 h to return to basal levels by 72 h. The plasma ALT activity in the PPAR-α −/− -DB mice showed a significantly different profile, increasing only after 24 h.
Liver injury peaked by 48 h and led to death of the mice, showing a delayed onset and progression of injury.
Histopathology confirmed the above biochemical findings. Liver sections stained with H&E were examined by light microscopy for multifocal necrosis, vacuolization, and inflammatory cell infiltration ( Fig. 1B ; Table 2 ). Both non-DB and DB PPAR-α −/− , mice showed significant steatosis before and after APAP administration. WT and PPAR-α −/− non-DB mice treated with APAP showed severe histopathologic changes in the liver as early as 6 h. Intense accumulation of erythrocytes in the central vein was evident, and inflammatory cell infiltration could be observed. The necrosis and vacuolization spread toward the periportal area over time, and by 24 h, the liver parenchyma was completely destroyed. On the other hand, WT-DB mice treated with the same dose of APAP showed less histological evidence of injury and hepatocellular necrosis (Fig. 1B , Table 2 ). By 72 h, the surviving WT-DB mice showed mitotic figures and regression of multifocal necrosis. The PPAR-α −/− -DB mice showed some evidence of cellular injury by 12 h, which spread by 36-48 h to cover two-thirds of the liver parenchyma.
Assessment of liver tissue repair
The S-phase DNA synthesis after APAP treatment in both the non-DB mice (WT and PPAR-α −/− ) was markedly decreased, leading to deficient repair and progression of liver injury typical of imminent hepatic failure. Treatment with APAP resulted in greater DNA synthesis in WT-DB mice (Fig. 1C) . S-phase DNA synthesis was significantly higher at 36, 48, and 72 h in the WT-DB group compared with the PPAR-α −/− -DB mice (Fig. 1C ). An early but transient increase in DNA synthesis by 6 h was observed in the PPAR-α −/− -DB mice that decreased by 24 h (Fig. 1C ).
PCNA immunohistochemical staining was consistent with the results of pulse-labeling studies. All appropriate controls, including non-DB and DB mice untreated with APAP, were also examined. Greater numbers of hepatocytes in S-phase were found in the WT-DB mice at 36 h compared with PPAR-α −/− -DB mice (19% in WT-DB vs. 4% in PPAR-α −/− DB mice). The WTnon-DB and PPAR-α −/− -non-DB livers did not show a significant increase in S-phase after APAP treatment (2 and 1.8% in WT and PPAR-α −/− non-DB mice at 0 h vs. 2.2 and 1.6% in WT and PPAR-α −/− non-dB mice at 24 h after APAP treatment). PPAR-α −/− -DB mice showed a distinct increase in S-phase positive cells by 6 h (12.4% at 6 h compared with 2.1% at 0 h), which decreased by 24 h. WT-DB mice showed robust DNA synthesis after 36 h and passage through successive stages of cell cycle (Fig. 1D ).
Cyp P450 isozymes in normal and diabetic WT and PPAR-α −/− mice
Cyp4a induction is a well-established marker of PPAR-α activation. A twofold induction was observed in Cyp4a protein in WT-DB mice (Fig. 2) . On the other hand, Cyp4a protein was decreased in the PPAR-α −/− -DB mice compared with non-DB PPAR-α −/− mice ( Fig. 2 ).
Because the bioactivation of APAP is mediated via hepatic microsomal cyp2e1 and to a minor extent cyp1a2 (36) , these P450 isozymes were investigated. No significant differences were found in Cyp2e1 and 1a1/1a2 protein levels between WT-non-DB and WT-DB mice (Fig. 2) . A 16 and 32% decrease in Cyp2e1 and 1a1/1a2 protein levels, respectively, was observed in PPAR-α −/− -DB mice compared with the non-DB counterparts (Fig. 2 ). Cyp2e1 activity as measured by p-nitrophenol hydroxylase activity was significantly lower in the PPAR-α −/− DB mice compared with the PPAR-α −/− non-DB mice (2324 ± 829 vs. 6290 ± 219 pmol/mg/min, respectively)
Gene expression analysis
Three separate hybridizations using a representative pooled sample (n=4) were carried out for each group at every time point. The gene expression intensities for every hybridization were first corrected with the local background and then normalized globally. Averages and SE of hybridization intensity were calculated for all genes at each time point, using Microsoft Excel software.
Gene expression changes at 12 h after APAP (compared with 0 h) were analyzed for the four treatment groups (WT-non-DB, WT DB, PPAR-α −/− non-DB, and PPAR-α −/− DB). Using hierarchical clustering (Cluster), six unique groups of genes were identified ( Interpretation of microarray data was done by examining several gene families according to their physiological function. We focused on five gene families. Genes involved in stress/oxidation stress/DNA damage were selected. Gadd45, Gadd153, HO-1, and EGR-1 were increased (13-, 6-, 3.5-, and 7-fold, respectively) in the WT-non-DB mice after APAP administration and to a similar extent in the PPAR-α −/− non-DB mice ( Fig. 4A and 4B ). In contrast, the WT-DB mice showed substantially attenuated increases in Gadd45, Gadd153, and HO-1 gene expression.
The second category of genes selected was immediate early protooncogenes. APAP-treated WT and PPAR-α −/− , non-DB and DB, mice showed marked increases in c-jun and c-fos protooncogenes ( Fig. 5A and 5B). jun-B and c-myc also showed a modest increase after APAP treatment. No significant differences were found in gene expression between non-DB and DB mice or either genotype, except gene expression of c-myc was not affected in the WT-DB after APAP treatment. Interestingly, PPAR-α −/− DB mice showed threefold higher c-fos gene expression compared with WT-DB mice at 12 h after APAP administration.
The third category of genes selected was P450 enzymes. Cyp4a10 and 4a14 were increased ∼10-fold in the WT-DB mice compared with WT non-DB cohorts. However, this increase was not seen in the PPAR-α −/− DB mice ( Fig. 6A and 6B ). Intriguingly, the PPAR-α −/− mice showed an increase in Cyp4a14 gene expression after APAP treatment. These data are consistent with the assessment of Cyp4a proteins by Western blot analysis (Fig. 2 ).
The fourth category of genes examined included HSPs. and not in the PPAR-α −/− -DB mice after APAP treatment. Diabetes increased the gene expression of p21, which was further increased after APAP treatment ( Fig. 8A and 8B ).
RT-PCR analyses
Microarray gene expression of several genes was confirmed via RT-PCR analysis. Gene expression trends of 15 genes are given in Table 4 . Gene expression of Cyp4a10 was significantly increased in WT-DB mice only and not PPAR-α −/− DB mice as seen in microarray studies. Similarly, RT-PCR confirmed gene expression trends of HO-1, Gadd 45, Gadd 153, EGR-1, and c-jun in the stress response genes to be similar to the microarray results. HSP gene expressions were significantly increased in the DB mice after APAP challenge in both WT and PPAR-α −/− mice. Cyclin D1 gene expression was ∼11-fold higher in the WT-DB mice, consistent with microarray analyses.
NF-κB activation in WT and PPAR-α −/− , non-DB and DB mice
NF-κB plays a critical role in modulating several cell survival and cell death mechanisms. Hence, we investigated the status of NF-κB at 4 and 12 h after APAP treatment (Fig. 9A) . Consistent with previous reports, APAP treatment inhibited NF-κB (37). However, NF-κB remained remarkably activated in the WT-DB mice at both time points. Basal expression of NF-κB in PPAR-α −/− DB mice was lower at 0 h followed by only modest activation at 4 h. PPAR-α −/− DB mice showed considerably lower NF-κB at 12 h after APAP compared with WT-DB mice. It is clear that activation of NF-κB in diabetes is mediated directly or indirectly via PPAR-α.
Assessment of cyclin D1, p38 MAPK, ERK1/2, and HSP70 proteins
Consistent with microarray analyses, cyclin D1 protein was markedly induced in WT-DB mice and to a lesser extent in PPAR-α −/− DB at 0 h (Fig. 9B) . However, in variance with the prediction by microarray studies, PPAR-α −/− DB mice showed greater increases in cyclin D1 protein at 12 h compared with WT-DB mice. This was consistent with higher DNA synthesis in the PPAR-α −/− DB mice at this time point. However, note that DNA synthesis in the PPAR-α −/− DB group is not sustainable and decreases after 24 h, allowing progression of liver injury. Phosphorylated-p38 MAPK was decreased in WT-DB mice compared with non-DB WT counterparts (Fig. 9B) . Non-DB PPAR-α −/− mice showed lower phospho-p38 MAPK. However, it must be kept in mind that these data are at least two steps removed from the microarray data: 1) translation of mRNA to protein and 2) availability of energy to phosphorlyate (p38-MAPK to phospho-p38-MAPK). To investigate whether other MAPKs are also affected in diabetes, we investigated the status of ERK1/2. No differences in ERK1/2 were found in either group. HSP 70 was decreased due to diabetes alone and was induced specifically in the WT-DB mice after APAP challenge (Fig. 9B) . The modulation of Hsp 70 protein was consistent with the microarray data.
CLC antimitosis
Lethality studies were performed to test the role of augmented tissue repair response in the WT-DB mice. This was accomplished by antimitotic intervention with CLC (1 mg/kg, i.p. in saline) injected at 2 and 30 h after APAP treatment. Blocking cell division by CLC treatment resulted in significant mortality in the WT-DB mice (WT-DB + APAP + CLC). Compared with the WT-DB + APAP + saline group that resulted in no mortality, there was 80% mortality in the CLC-treated group of DB mice. As anticipated, control groups of mice treated with CLC alone did not show any adverse effects or any mortality (Table 5 ). Biochemical parameters of liver injury (ALT) were not measured in this study.
DISCUSSION
The diabetic state protects mice from hepatotoxicants (1-4). On the other hand, diabetes increases the susceptibility of rats to the same compounds (16) (17) 19) . We have reported resistance of DB mice to four structurally and mechanistically dissimilar hepatotoxicants, confirming that there is a fundamental species difference between DB rats and mice (2) . Diabetic mice are resistant to a normally lethal dose of APAP. In earlier investigations using the STZinduced DB Swiss Webster mice, similar resistance was observed against hepatotoxicant, including APAP (1, 2). Findings of those studies also suggested that greater clearance of APAP may play a role in DB-mediated resistance. APAP clearance and bioactivation were the two potential mechanisms selected for additional investigation. First, our studies demonstrate 34% lower plasma half-life of APAP in the DB mice along with twofold higher clearance of APAP, presumably due to a 10-fold increase in urine output in the DB mice (2). Second, we investigated whether or not diabetes decreases bioactivation of APAP. Three independent indirect markers of actual reactive intermediate argue against this. First, covalent binding of 14 C-APAP was not different between DB and non-DB mice. Second, selective protein arylation of cytosolic acetaminophen binding proteins, which has served as an indirect indicator of net availability of reactive electrophile in the liver, was also similar between non-DB and DB mice (11, 38) . Third, the degree of GSH depletion was also similar between non-DB and DB mice, further strengthening the observation that equal bioactivation occurred in both groups. Hence, it appears that a decrease in Cyp2e1 and 1a1/1a2-mediated bioactivation is not the mechanism by which the marked hepatotoxic protection against APAP toxicity is achieved in the DB mice.
We investigated the role of diabetes-induced PPAR-α activation in mediating the resistance in DB mice because peroxisome proliferators are known to protect mice against this and other hepatotoxins. Several studies have shown that STZ-induced diabetes results in induction of cyp4a mRNA and protein, and also acyl-CoA oxidase protein, classical markers of PPAR-α activation (13) (14) (15) . PPAR-α mRNA is also increased in the diabetic state (14) . Only one other reported study has examined cyp4a expression in STZ-induced diabetic PPAR-α −/− mice (13).
Our data are consistent with their findings that cyp4a induction in diabetes requires PPAR-α. However, neither cyp4a mRNA nor protein in WT and PPAR-α −/− mice was quantitated in these studies. Our RT-PCR studies indicate that cyp4a10 and cyp4a14 mRNA levels are highly induced (∼10-fold) in WT-DB mice. However, the proteins estimated via Western analysis were cyp4a1, because the commercially available antibodies recognize rat/mouse cyp4a1. This might explain why we had only a modest increase in cyp4a protein, whereas other peroxisome proliferators result in more robust cyp4a induction.
Does PPAR-α activation influence the ability of the liver to repair after APAP challenge? PPAR-α activation, following treatment with peroxisome proliferators, affords protection from toxicity of several hepatotoxicants, including APAP (8, (10) (11) (12) . The protective mechanism is unrelated to decreased bioactivation or to increased detoxification by glutathione (9, 10) . In another recent study, PPAR-α −/− mice challenged with CCl 4 developed acute liver failure, with 50% greater mortality compared with WT controls (39) . The authors suggest that PPAR-α may be involved in mitigating liver inflammation. Furthermore, recent evidence points to the role of PPAR-α in liver regeneration and wound healing (7, 40) . Peak of S-phase DNA synthesis is delayed almost by 24 h in PPAR-α −/− mice after partial hepatectomy (7). PPAR-α activation is known to increase cell proliferation and to decrease apoptosis, both of which can increase the ability of the liver to repair tissue after chemical injury. These observations are consistent with the hypothesis that PPAR-α activation may be a protective mechanism in diabetic mice. Our data from lethality experiments with WT and PPAR-α −/− -DB mice support this hypothesis. WT-DB mice were resistant to APAP toxicity as anticipated from studies with Swiss mice and showed sustained tissue repair. In the WT-DB mice, no differences in cyp2e1 or 1a2 expression were evident, thereby diminishing the possible role of lower bioactivation of APAP. In addition, greater clearance of APAP in DB mice may reduce initial bioactivation-based injury of APAP. The DNA synthesis in the PPAR-α −/− -DB mice decreased by 24-36 h, thereby suggesting that this cell division may not be sustainable without PPAR-α in the DB state. However, the PPAR-α −/− DB mice exhibited lower initial injury and higher DNA synthesis, suggesting that other mechanisms are involved. Several mechanisms may be involved in decreased initial liver injury. We have found lower Cyp2e1 and 1a2 in PPAR-α −/− DB mice that may lead to lower bioactivation. However, based on our previous studies in Swiss Webster mice, it is unlikely that decreased bioactivation is the mechanism (2). In those studies, a 50% decrease in hepatic Cyp2e1 and 1a2 did not change the amount of reactive intermediate produced. However, although speculative, possibility exists that several other events subsequent to covalent binding of APAP to liver target proteins may be responsible for decreased liver injury. To examine the role of sustained cell division, we blocked cell division in the DB mice with CLC. CLC antimitosis led to an increase in mortality of WT-DB + APAP, suggesting a pivotal role for tissue repair in animal survival, regardless of the extent of initial liver injury. This lends strong support to the notion that robust tissue repair obtunds progression of liver injury in the DB mice.
To further understand the molecular basis of this resistance, we used microarrays as a tool to generate hypotheses for differential susceptibility of WT and PPAR-α −/− -DB mice. Greater increases in stress response genes were evident in WT-non-DB mice after APAP challenge than in the WT-DB mice (Fig. 4) . Most striking was the marked increase in gene expression of the cell cycle regulator, cyclin D1, in the WT-DB mice (Fig. 8) . Protein expression of cyclin D1 is also increased as a result of diabetes. However, following APAP treatment, the PPAR-α −/− DB mice show a robust increase in cyclin D1. This is not consistent with microarray findings and hence may reflect posttranscriptional regulation of cyclin D1 in PPAR-α −/− mice. Higher cyclin D1 levels were expected at 12 h in the PPAR-α −/− DB mice, because significant DNA synthesis was detected at this time.
A role of HSPs is also evident in the diabetic mice after APAP challenge. Diabetes alone did not cause any major changes in gene expression of HSPs, except for a decrease in HSP 70 and increases in HSP 60 and 86 (Fig. 7) . These findings are similar to those reported by Yamagishi et al. (41) . Our studies confirm that HSP 70 protein is also decreased in DB mice. Induction of HSP 70 after APAP treatment occurs only in the WT-DB mice and not in the PPAR-α −/− DB mice, suggesting that PPAR-α may be required and indirectly responsible for this response. Gene expression data of HSPs 105 and 84 also show some PPAR-α dependence in the robustness of their response. Similarly, gene expression of HSP 25 is selectively increased in the WT-DB mice. However, the mechanisms underlying the increases in HSPs 25, 86, and 105 remain to be investigated. Induced HSPs protect against liver injury of ischemic-reperfusion, CCl 4 , thioacetamide, bromobenzene, and APAP (42) (43) (44) (45) (46) . It has been suggested that proteins covalently bound to toxicants may stimulate HSP synthesis (46) . Similarly, microinjection of chemically denatured proteins into cells can elicit increased HSP synthesis (47) . However, the mechanism of enhanced HSP induction in the DB mice after APAP treatment is not known. The plausible involvement of PPAR-α in HSP regulation is a novel hypothesis.
The molecular mechanisms by which PPAR-α might directly or indirectly affect cell survival and cell division are beginning to be revealed in recent research from several laboratories (Fig.  10 ). Several lines of evidence suggest that activation of the redox-sensitive transcription factor, NF-κB, is important in PPAR-α-mediated effects (48, 49) . The activation of NF-κB may be due to increased oxidative stress after peroxisome proliferation (50) or due to altered cytokine signaling (51) . It can be speculated that PPAR-α-mediated increases of acyl-CoA oxidase, cyp4a, peroxisomal β-oxidation enzymes, and hydrogen peroxide coupled with decreases in catalase in diabetes (52) activate oxidative stress-responsive transcription factors such as NF-κB. However, the question is how much does PPAR-α contribute to the activation of NF-κB? Our studies shed some light on this question. NF-κB activation that occurs selectively in the DB mice after APAP is markedly diminished in the absence of PPAR-α (PPAR-α −/− DB mice). This is consistent with our hypothesis that enhanced oxidative stress induced indirectly via PPAR-α is responsible for activating certain cell survival strategies (e.g., HSPs, cell proliferation genes). More mechanistic investigations are needed for a better understanding. Also, activation of the transcription factors AP-1 and Egr-1 do not occur with peroxisome proliferators (53).
A newer avenue being explored is the cross-talk between PPAR-α and p38 MAPK (reviewed in refs 54 and 55). Diabetes activates PPAR-α and other stress pathways, which might indirectly lead to activation of immediate early genes responsible for cell survival or division. Cyclin D1 has a key growth-regulating role in liver cells. Overexpression of cyclin D1 in primary rat cultures of adult hepatocytes is sufficient to promote progression through the G 1 checkpoint (56) . Considerable evidence points to negative regulation of cyclin D1 gene by p38 (57) (58) (59) . In cells co-expressing MKK3 and p38, significant inhibition of cyclin D1 was observed (57) . In our studies, WT-DB mice showed a nearly 2.5-fold decrease in p38 gene expression levels accompanied with a decrease in protein levels. This decrease might well explain the higher gene expression of cyclin D1. It is not clear, however, whether p38-MAPK is the key factor regulating cyclin D1 levels. Evidence from our Western blot analyses argues against the strong involvement of p38-MAPK in the increase of cyclin D1. Cyclin D1 is regulated via several factors. The cyclin D1 promoter contains multiple regulatory elements (AP1, E2F, Oct, SP1/SP3, NF-κB) and some uncharacterized elements that play an important role in its regulation (60, 61) . However, the precise mechanism behind increased cyclin D1 mRNA in the DB mice remains to be investigated.
In conclusion, we report a novel role of diabetes-induced PPAR-α as a hepatoprotective mechanism involving stimulation of tissue repair upon hepatotoxic injury. Greater HSP induction accompanied with robust liver tissue repair in the DB mice was evident after APAP challenge. More mechanistic investigations are needed to establish which key genes are modulated by PPAR-α in diabetes to afford this marked hepatoprotection by stimulation of early onset and robust tissue repair. 
a On day 0, male WT (129SV) and PPAR-α -/-mice (28-35 g) were injected with either STZ (150 mg/kg, i.p., in citrate buffer, pH 4.3) or citrate buffer (10 ml/kg) alone. On day 10, both groups (STZ and vehicle treated) were injected with a single dose of acetaminophen (APAP, 600 mg/kg, i.p., in warm basic saline, pH 8). Liver samples were collected for histopathology at 0, 6, 12, 24, 36, 48, and 72 h after APAP treatment (see Materials and Methods). Four hematoxylin and eosinstained slides from each group, each from a separate animal, were scored. b The extent of liver necrosis was estimated semiquantitatively, and lesions were scored as multifocal necrosis. Scoring was as follows: 0, no necrosis; 1, minimal, defined as only occasional necrotic cells in any lobule; 2, mild, defined as less than one-third of the lobular structure affected; 3, moderate, defined as between one-third and two-thirds of the lobular structure affected; 4, severe, defined as greater than two-thirds of the lobular structure affected; 5, more severe, defined as damage to most of the parenchyma of the liver. Gene expression analyses in WT and PPAR-α -/-, non-DB and DB mice after acetaminophen treatment using real-time PCR analyses
On day 0, male 129SV (27-32 g) were injected with either STZ (150 mg/kg, i.p. in citrate buffer, pH 4.3) or citrate buffer (10 ml/kg) alone. On day 10, DB mice were divided into two groups. Plasma glucose was estimated on day 10. Both groups were injected with a single dose of acetaminophen (APAP, 600 mg/kg, i.p. in warm basic saline, pH 8). Livers were excised under diethyl ether anesthesia and flash frozen. Total RNA was isolated and mRNA transcripts for selected genes were quantitated using real-time polymerase chain reaction (RT-PCR) as described under methods. Hepatic RNA from 4 separate mice in each group was analyzed in duplicates. Results are expressed as average antilog of threshold cycle (C T ) value relative to WT-non-DB mice at 0 h after APAP treatment. 6, 12, 24, 36, 48 , and 72 h after APAP treatment, plasma and livers were collected as described in Materials and Methods. Four mice were treated per group per time point, except for non-DB groups treated with APAP, in order to obtain an adequate number of surviving mice (n=8 for 36 h WT-non-DB and PPAR-α -/--non-DB group, n=8 for 48 and 72 h WT-DB group, n=8 for 48 h PPAR-α -/--DB group). Results expressed as means ± SE. ! Significantly lower than non-DB control at the same time point. # Significantly higher than respective 0 h control. P≤0.05. B) Representative photomicrographs of hematoxylin and eosin-stained liver sections over a time course after APAP administration to WT and PPAR-α -/-, DB and non-DB mice. Details are the same as in Figure 1A and in Materials and Methods. Scoring was as follows: 0, no necrosis; 1, minimal, defined as only occasional necrotic cells in any lobule; 2, mild, defined as less than one-third of the lobular structure affected; 3, moderate, defined as between one-third and two-thirds of the lobular structure affected; 4, severe, defined as greater than two-thirds of the lobular structure affected; 5, more severe, defined as damage to most of the parenchyma of the liver. WT non-DB after 12 h (a); WT-DB after 12 h (b); PPAR-α -/-non-DB after 12 h (c); PPAR-α -/-DB after 12 h (d); WT-DB after 36 h (e); and PPAR-α -/-DB after 36 h (f). Both non-DB and DB mice treated with saline (vehicle for APAP) alone showed no necrosis (data not shown). C, central vein; P, pyknotic nuclei; N, areas of necrosis. Magnification, 400×. C) 3 H-T incorporation into hepatonuclear DNA after APAP administration to non-DB and DB, WT and PPAR-α -/-mice. Treatment details are the same as in Figure 1A and in Materials and Methods. mice. See Materials and Methods for sample collection, preparation, and assay procedures (n=4). Cyp4a densitometric units in WT non-DB, WT DB, PPAR-α -/-non-DB, and PPAR-α -/-DB were 7.3 ± 0.4, 17.1 ± 1.0,* 17.1 ± 2.0, and 7.9 ± 1.7,* respectively. Cyp2e1 densitometric units in WT non-DB, WT DB, PPAR-α -/-non-DB, and PPAR-α -/-DB were 11.9 ± 0.7, 13.2 ± 1.2, 13.6 ± 0.5, and 11.4 ± 0.5*, respectively. Cyp1a1/1a2 densitometric units in WT non-DB, WT DB, PPAR-α -/-non-DB, and PPAR-α -/-DB were 13.0 ± 0.9, 11.9 ±0.7, 14.9 ± 0.7, and 10.0 ± 2.0,* respectively. * Significantly different from the respective nondiabetic control. P≤0.05. Diabetes leads to activation of PPAR-α and consequent increased oxidative stress. Redox sensitive transcription factor NF-κB can be activated via multiple pathways either directly or indirectly via PPAR-α. After APAP treatment, NF-κB is activated selectively in the WT-DB mice, in a PPAR-α-dependent manner. Cyclin D1 gene and protein expression, which was increased in the WT-DB mice, can be influenced directly via NF-κB or other regulators such as p38-MAPK. p38-MAPK, known to negatively regulate cyclin D1, is significantly decreased in diabetes. Higher cyclin D1 expression is consistent with earlier progression of hepatocytes from G 0 to G 1 cell cycle phases after APAP challenge.
